Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy

• Published in: Cancer letters Vol. 353; no. 2; pp. 160 - 166
• Main Authors: Sullivan, Ivana, Salazar, Juliana, Majem, Margarita, Pallarés, Cinta, del Río, Elisabeth, Páez, David, Baiget, Montserrat, Barnadas, Agustí
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier Ireland Ltd 28.10.2014; Elsevier Limited
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Agents - pharmacology; Cancer therapies; Carboplatin - pharmacology; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - mortality; Carcinoma, Non-Small-Cell Lung - pathology; Chemotherapy; Cisplatin - pharmacology; Deoxyribonucleic acid; Disease-Free Survival; DNA; DNA Helicases - genetics; DNA Repair; DNA-Binding Proteins - genetics; Endonucleases - genetics; Female; Genetic Association Studies; Genomes; Hematology, Oncology and Palliative Medicine; Humans; Kaplan-Meier Estimate; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - mortality; Lung Neoplasms - pathology; Male; Middle Aged; Mortality; Neoplasm Staging; Non-small cell lung cancer; Ovarian cancer; Platinum-based chemotherapy; Polymorphism, Single Nucleotide; Prospective Studies; Proteins; Radiation therapy; Radiotherapy; Response rates; Single nucleotide polymorphisms; Studies; Treatment Outcome; Xeroderma Pigmentosum Group D Protein - genetics; Single nucleotide polymorphisms; Radiotherapy; DNA repair; Platinum-based chemotherapy; Non-small cell lung cancer
• ISSN: 0304-3835; 1872-7980
• DOI: 10.1016/j.canlet.2014.07.023

Highlights • High DNA repair capacity has been related to chemoresistance in NSCLC. • The complexity of DNA repair mechanisms explains the role of multiple genes as putative biomarkers. • Genetic variants in DNA repair genes are associated with platinum efficacy in NSCLC.